Bio-Rad Laboratories (NYSE:BIO.B) develops, manufactures and sells products and services used in life science research and clinical diagnostics. The company serves academic and government laboratories, pharmaceutical and biotechnology companies, hospitals, clinical laboratories and other healthcare organizations.
Bio-Rad’s Life Science segment provides instruments, reagents, software and consumables for applications including gene expression analysis, polymerase chain reaction, digital PCR, protein research, cell biology, chromatography, electrophoresis and laboratory quality control. Its Clinical Diagnostics segment offers systems and products used in areas such as blood typing and immunohematology, diabetes monitoring, autoimmune testing, infectious disease testing and quality-control management.
Founded in 1952 by David and Alice Schwartz, Bio-Rad is headquartered in Hercules, California, and serves customers through operations and distribution networks in North America, Europe, Asia and other international markets. The company operates globally under the leadership of Chairman and Chief Executive Officer Norman D. Schwartz.
